Delaying treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for hematological malignancies: A prospective randomized trial

Bone Marrow Transplantation

Volumn 24, Issue 2, 1999, Pages 147-151

  Ciernik, I F ^a   Schanz, U ^b   Gmur J ^b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b NONE

Author keywords

Bone marrow transplantation; G CSF granulocyte colony stimulating factor; Hematopoietic growth factors; Hematopoietic recovery; Neutrophil engraftment

Indexed keywords

AMPHOTERICIN B; ANTIBIOTIC AGENT; BUSULFAN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETOPOSIDE; FLUCONAZOLE; METHOTREXATE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BACTERIAL INFECTION; BLOOD DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COST; ERYTHROCYTE COUNT; FEMALE; FEVER; GRAFT VERSUS HOST REACTION; GRANULOCYTE; HEMATOMA; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE COUNT; MALE; MORBIDITY; MORTALITY; MUCOSA INFLAMMATION; MYCOSIS; MYELODYSPLASTIC SYNDROME; NEUTROPHIL; NONHODGKIN LYMPHOMA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RASH; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTE COUNT; VEIN OCCLUSION; VIRUS INFECTION;

EID: 0032780151     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701872     Document Type: Article

References (27)

1. Schriber JR, Chao NJ, Long GD et al. Granulocyte colony-stimulating factor after allogenic bone marrow transplantation. Blood 1994; 84: 1680-1684.
2. Gisselbrecht C, Prentice H, Bacigalupo A et al. Placebo controlled phase III trial of lenograstim in bone marrow transplantation. Lancet 1994; 343: 696-700.
3. Locatelli F, Pession A, Zecca M. Use of recombinant G-CSF in children given allogeneic bone marrow transplantation for acute and chronic leukemia. Bone Marrow Transplant 1996; 17: 31-37.
4. Schmitz N, Bacigalupo A, Labopin M et al. Transplantation of peripheral blood progenitor cells from HLA-identical sibling donors. Br J Haematol 1996; 95: 715-723.
5. Masoaka T, Takaku F, Kato S et al. Recombinant human G-CSF in allogeneic bone marrow transplantation. Exp Haematol 1989; 17: 1047-1050.
6. Linch DC, Scarffe H, Proctor S et al. A randomized, vehicle controlled dose finding study of glycosylated recombinant human G-CSF after bone marrow transplantation. Bone Marrow Transplant 1993; 11: 307-311.
7. McQuaker I, Hunter A, Pacey S et al. Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral blood stem cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit. J Clin Pathol 1997; 15: 451-457.
8. Klumpp T, Mangan K, Goldberg S et al. G-CSF accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: a prospective randomized trial. J Clin Oncol 1995; 13: 1323-1327.
9. Bolwell BJ, Pohlman B, Andersen S et al. Delayed G-CSF after autologous progenitor cell transplantation: a prospective randomized trial. Bone Marrow Transplant 1998; 21: 401-407.
10. Atkinson K, Rowlings P, Pelz C, Horowitz M and IBMTR: effects of G-CSF and GM-CSF on outcomes following HLA-identical sibling bone marrow transplants for early leukemia. Blood 1996; 88 (Suppl. 1): 2449.
11. Inukai T, Sugita K, Iijima K et al. Leukemic cells with 1 Iq23 translocation express granulocyte colony-stimulationg factor (G-CSF) receptor and their proliferation is stimulated with G-CSF. Leukemia 1998; 12: 382-389.
12. Avalos BR. The granulocyte colony-stimulating factor receptor and its role in disorders of granulopoiesis. Leuk Lymphoma 1998; 28: 265-273.
13. ASCO. American Society of Clinical Oncology recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 1994; 12: 2471-2508.
14. Powles R, Smith C, Milan S et al. Human recombinant GM-CSF in allogeneic bone marrow transplantation for leukemia: double-blind, placebo-controlled trial. Lancet 1990; 336: 1417-1420.
15. De Witte T, Gratwohl A, Van Der Lely N. Recombinant human granulocyte-macrophage colony-stimulating factor accelerates neutrophil and monocyte recovery after allogeneic T-cell depleted bone marrow transplantation. Blood 1992; 79: 1359-1365.
16. ASCO. Update of recomendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. J Clin Oncol 1996; 14: 1957-1960.
17. Rowe JM, Ciobanu N, Ascensao J et al. Recommended guidelines for the management of autologous and allogeneic bone marrow transplantation. Ann Intern Med 1994; 120: 143-157.
18. Gupta P, Tiley C, Powles R et al. No increase in relapse in patients with myeloid leukemias receiving rhGM-CSF after allogeneic bone marrow transplantation. Bone Marrow Transplant 1992; 9: 491-493.
19. Faucher C, Lecorroller A, Chabannon C et al. Administration of G-CSF can be delayed after transplantation of autologous G-CSF-primed blood stem cells - a randomized study. Bone Marrow Transplant 1996; 17: 533-536.
20. Tarella C, Castellino C, Locatelli F et al. G-CSF administration following peripheral blood progenitor cell autograft in lymphoid malignancies: evidence for clinical benefits and reduction of treatment costs. Bone Marrow Transplant 1998; 21: 369-373.
21. Torres Gomez A, Jimenez M, Alvarez M et al. Optimal timing of granulocyte colony-stimulating factor (G-CSF) administration after bone marrow transplantation. A prospective randomized study. Ann Hematol 1995; 71: 65-70.
22. Pavletic S, Bishop MR, Tarantolo SR et al. Hematopoietic recovery after allogeneic blood stem-cell transplantation compared with bone marrow transplantation in patients with hematologic malignancies. J Clin Oncol 1998; 15: 1608-1616.
23. Eder M, Geissler G, Ganser A. IL-3 in the clinic. Stem Cells 1997; 15: 327-333.
24. Miyazaki H. Update on thrombopoietin in preclinical and clinical trials. Curr Opin Hematol 1998; 5: 197-202.
25. Schulman KA, Dorsainvil D, Yabroff KR et al. Prospective economic evaluation accompanying a trial of GM-CSF/IL-3 in patients undergoing autologous bone marrow transplantation for Hodgkin's and non-Hodgkin's disease. Bone Marrow Transplant 1998; 21: 607-614.
26. Lemoli RM, Rosti G, Visani G et al. Concomitant and sequential administration of recombinant human granulocyte colony-stimulating factor and recombinant human interleukin-3 to accelerate hematopoietic recovery after autologous bone marrow transplantation for malignant lymphoma. J Clin Oncol 1998; 14: 3018-3025.
27. Zeng D, Dejbakhsh-Jones S, Strober S. Granulocyte colony-stimulating factor reduces the capacity of blood mononuclear cells to induce graft-versus-host disease: impact on blood progenitor cell transplantation. Blood 1997; 90: 453-463.